Literature DB >> 1261102

The protein binding of diazepam and N-demethyldiazepam in patients with poor renal function.

L Kangas, J Kanto, J Forsström, E Iisalo.   

Abstract

The plasma protein binding of diazepam and of its main metabolite, N-demethyldiazepam, was measured in patients with renal disease and in healthy volunteers by ultracentrifugation. The total and non-protein bound concentrations of diazepam and N-demethyldiazepam, and the concentration of unconjugated oxazepam in the plasma were determined by gas chromatography after an oral 10 mg dose of diazepam. In the volunteers 98% of diazepam and N-demethyldiazepam were bound to the plasma proteins. In patients with renal disease the corresponding values were 92% and 95%, respectively. In the patients with renal disease no correlation could be found between the percent protein binding of diazepam or N-demethyldiazepam in the plasma and the serum creatinine concentration. Considerable variations in diazepam concentrations at 1 and 24 hours and in N-demethyldiazepam concentrations at 24 hours were found in the patients with renal disease. In contrast to the volunteers, 5 patients out of 28 with renal disease had measurable amounts of unconjugated oxazepam in the plasma. The deficient ability of the plasma proteins of patients with renal disease to bind diazepam may increase its clinical effect.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261102

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  16 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Sedation for fibreoptic bronchoscopy.

Authors:  M P Shelley; P Wilson; J Norman
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

Review 3.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

4.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

5.  Pharmacokinetics of intravenous anaesthetics: implications for clinical use.

Authors:  M M Ghoneim; K Korttila
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 6.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

7.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 8.  Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.

Authors:  J H Kanto
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

9.  Transfer of nitrazepam across the human placenta.

Authors:  L Kangas; J Kanto; R Erkkola
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.